Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Data Interpretation, Statistical | 1 | 2018 | 297 | 0.580 |
Why?
|
| Models, Statistical | 1 | 2018 | 574 | 0.510 |
Why?
|
| Quality Indicators, Health Care | 4 | 2022 | 144 | 0.490 |
Why?
|
| Inappropriate Prescribing | 2 | 2022 | 18 | 0.420 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2012 | 134 | 0.340 |
Why?
|
| Nursing Homes | 2 | 2022 | 109 | 0.330 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 3 | 2012 | 16 | 0.280 |
Why?
|
| Health Behavior | 2 | 2018 | 183 | 0.260 |
Why?
|
| Hospitals, Urban | 2 | 2021 | 54 | 0.240 |
Why?
|
| Ticlopidine | 5 | 2012 | 25 | 0.240 |
Why?
|
| Re-Irradiation | 1 | 2022 | 15 | 0.220 |
Why?
|
| Patient Discharge | 2 | 2017 | 300 | 0.200 |
Why?
|
| Counseling | 2 | 2013 | 145 | 0.200 |
Why?
|
| Sleep Wake Disorders | 1 | 2022 | 115 | 0.190 |
Why?
|
| Women | 1 | 2021 | 25 | 0.190 |
Why?
|
| Research Support as Topic | 1 | 2021 | 80 | 0.190 |
Why?
|
| Research Personnel | 1 | 2021 | 67 | 0.190 |
Why?
|
| Cardiovascular Diseases | 3 | 2014 | 827 | 0.190 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2021 | 122 | 0.180 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2021 | 118 | 0.180 |
Why?
|
| Anti-HIV Agents | 1 | 2022 | 149 | 0.180 |
Why?
|
| Stroke | 4 | 2010 | 965 | 0.180 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2022 | 137 | 0.180 |
Why?
|
| Reminder Systems | 1 | 2018 | 16 | 0.170 |
Why?
|
| Sexual and Gender Minorities | 1 | 2022 | 192 | 0.170 |
Why?
|
| Electronic Health Records | 1 | 2022 | 319 | 0.170 |
Why?
|
| Carcinoma | 1 | 2022 | 436 | 0.170 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 239 | 0.160 |
Why?
|
| Islam | 1 | 2018 | 34 | 0.160 |
Why?
|
| Women's Health | 3 | 2014 | 100 | 0.160 |
Why?
|
| Students | 1 | 2018 | 147 | 0.150 |
Why?
|
| Quality Improvement | 2 | 2022 | 428 | 0.150 |
Why?
|
| Psychometrics | 1 | 2018 | 327 | 0.150 |
Why?
|
| Longitudinal Studies | 2 | 2018 | 1019 | 0.150 |
Why?
|
| Community-Acquired Infections | 1 | 2017 | 63 | 0.140 |
Why?
|
| Patient Safety | 1 | 2018 | 212 | 0.140 |
Why?
|
| Humans | 27 | 2022 | 86617 | 0.140 |
Why?
|
| Affect | 1 | 2018 | 386 | 0.140 |
Why?
|
| Pain Management | 1 | 2016 | 127 | 0.130 |
Why?
|
| Pneumonia | 1 | 2017 | 179 | 0.130 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 1801 | 0.130 |
Why?
|
| Head and Neck Neoplasms | 1 | 2022 | 1052 | 0.130 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 392 | 0.130 |
Why?
|
| Brain Ischemia | 2 | 2010 | 398 | 0.120 |
Why?
|
| Sleep | 2 | 2022 | 444 | 0.120 |
Why?
|
| Risk Reduction Behavior | 1 | 2014 | 98 | 0.120 |
Why?
|
| HIV Infections | 1 | 2022 | 772 | 0.120 |
Why?
|
| Medically Uninsured | 2 | 2014 | 58 | 0.110 |
Why?
|
| Patient Readmission | 1 | 2017 | 329 | 0.110 |
Why?
|
| Thienopyridines | 1 | 2012 | 1 | 0.110 |
Why?
|
| Time Factors | 3 | 2018 | 5209 | 0.110 |
Why?
|
| Health Promotion | 1 | 2014 | 160 | 0.110 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 484 | 0.110 |
Why?
|
| Weight Gain | 1 | 2013 | 123 | 0.100 |
Why?
|
| Self Care | 1 | 2013 | 164 | 0.100 |
Why?
|
| Patient Compliance | 1 | 2013 | 227 | 0.100 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2013 | 103 | 0.100 |
Why?
|
| Chicago | 4 | 2018 | 1379 | 0.100 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2009 | 22 | 0.100 |
Why?
|
| Nursing Records | 1 | 2010 | 1 | 0.100 |
Why?
|
| Life Style | 1 | 2011 | 189 | 0.100 |
Why?
|
| Aspirin | 2 | 2010 | 156 | 0.090 |
Why?
|
| Patient Admission | 1 | 2010 | 112 | 0.090 |
Why?
|
| Documentation | 1 | 2010 | 98 | 0.090 |
Why?
|
| Menopause | 1 | 2010 | 71 | 0.090 |
Why?
|
| Lipoproteins, HDL | 1 | 2010 | 96 | 0.090 |
Why?
|
| Illinois | 4 | 2014 | 462 | 0.090 |
Why?
|
| Women's Health Services | 1 | 2009 | 15 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2013 | 770 | 0.090 |
Why?
|
| Primary Prevention | 1 | 2009 | 85 | 0.080 |
Why?
|
| Platelet Aggregation | 1 | 2008 | 44 | 0.080 |
Why?
|
| Aged | 8 | 2021 | 18402 | 0.080 |
Why?
|
| Vitamin D | 1 | 2010 | 261 | 0.080 |
Why?
|
| Depression | 1 | 2011 | 473 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 508 | 0.070 |
Why?
|
| Female | 14 | 2018 | 44509 | 0.070 |
Why?
|
| Medical Audit | 1 | 2006 | 41 | 0.070 |
Why?
|
| Atherosclerosis | 1 | 2010 | 244 | 0.070 |
Why?
|
| Hospital Units | 1 | 2006 | 30 | 0.070 |
Why?
|
| Coronary Artery Disease | 1 | 2011 | 350 | 0.070 |
Why?
|
| Dermatomyositis | 1 | 2006 | 17 | 0.070 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2009 | 275 | 0.070 |
Why?
|
| Obesity | 1 | 2013 | 963 | 0.070 |
Why?
|
| Mycophenolic Acid | 1 | 2006 | 87 | 0.070 |
Why?
|
| Middle Aged | 10 | 2018 | 25017 | 0.070 |
Why?
|
| Sex Distribution | 2 | 2021 | 173 | 0.070 |
Why?
|
| Pyridines | 1 | 2007 | 310 | 0.070 |
Why?
|
| Analysis of Variance | 3 | 2014 | 912 | 0.070 |
Why?
|
| Quality of Life | 1 | 2013 | 1583 | 0.060 |
Why?
|
| Surveys and Questionnaires | 3 | 2018 | 2501 | 0.060 |
Why?
|
| Heart Failure | 1 | 2013 | 1204 | 0.060 |
Why?
|
| Male | 9 | 2022 | 40958 | 0.060 |
Why?
|
| Registries | 1 | 2006 | 702 | 0.060 |
Why?
|
| Hydroxyurea | 1 | 2022 | 239 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 1621 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 133 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2022 | 270 | 0.050 |
Why?
|
| Skilled Nursing Facilities | 1 | 2022 | 41 | 0.050 |
Why?
|
| Carboplatin | 1 | 2022 | 286 | 0.050 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 45 | 0.050 |
Why?
|
| Drug Prescriptions | 1 | 2022 | 141 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2022 | 556 | 0.050 |
Why?
|
| Comorbidity | 2 | 2017 | 943 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2022 | 460 | 0.050 |
Why?
|
| Leadership | 1 | 2022 | 134 | 0.050 |
Why?
|
| Sexual Behavior | 1 | 2022 | 302 | 0.040 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 301 | 0.040 |
Why?
|
| Adult | 6 | 2018 | 25640 | 0.040 |
Why?
|
| Homosexuality, Male | 1 | 2022 | 298 | 0.040 |
Why?
|
| Medication Errors | 1 | 2018 | 39 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2018 | 111 | 0.040 |
Why?
|
| Accidental Falls | 1 | 2018 | 50 | 0.040 |
Why?
|
| Pressure Ulcer | 1 | 2018 | 42 | 0.040 |
Why?
|
| Religion | 1 | 2018 | 87 | 0.040 |
Why?
|
| Focus Groups | 1 | 2018 | 155 | 0.040 |
Why?
|
| Plasma Exchange | 2 | 2009 | 29 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 999 | 0.040 |
Why?
|
| Data Collection | 2 | 2010 | 372 | 0.040 |
Why?
|
| Logistic Models | 1 | 2021 | 1185 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2022 | 581 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2017 | 4212 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1313 | 0.030 |
Why?
|
| Home Care Services | 1 | 2017 | 72 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2017 | 7990 | 0.030 |
Why?
|
| Analgesics | 1 | 2016 | 119 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2009 | 2887 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2016 | 321 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2008 | 894 | 0.030 |
Why?
|
| United States | 2 | 2021 | 6665 | 0.030 |
Why?
|
| Social Class | 1 | 2014 | 127 | 0.030 |
Why?
|
| Emigrants and Immigrants | 1 | 2014 | 44 | 0.030 |
Why?
|
| Educational Status | 1 | 2014 | 188 | 0.030 |
Why?
|
| Length of Stay | 1 | 2017 | 700 | 0.030 |
Why?
|
| New York | 1 | 2013 | 69 | 0.030 |
Why?
|
| Psychotherapy, Group | 1 | 2013 | 33 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 3636 | 0.030 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2012 | 4 | 0.030 |
Why?
|
| Risk Factors | 2 | 2017 | 5417 | 0.030 |
Why?
|
| Actigraphy | 1 | 2013 | 51 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2013 | 105 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2013 | 80 | 0.030 |
Why?
|
| Thiophenes | 1 | 2012 | 48 | 0.030 |
Why?
|
| Polysomnography | 1 | 2013 | 151 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 2436 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 1849 | 0.030 |
Why?
|
| Motor Activity | 1 | 2014 | 327 | 0.030 |
Why?
|
| Overweight | 1 | 2013 | 118 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2013 | 231 | 0.030 |
Why?
|
| Reference Values | 1 | 2013 | 674 | 0.030 |
Why?
|
| Diet | 1 | 2014 | 443 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2008 | 2767 | 0.020 |
Why?
|
| Piperazines | 1 | 2012 | 272 | 0.020 |
Why?
|
| Nursing Evaluation Research | 1 | 2010 | 3 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 567 | 0.020 |
Why?
|
| Forms and Records Control | 1 | 2010 | 16 | 0.020 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2010 | 13 | 0.020 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2010 | 5 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 297 | 0.020 |
Why?
|
| Abdominal Fat | 1 | 2010 | 13 | 0.020 |
Why?
|
| Calcifediol | 1 | 2010 | 21 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2011 | 232 | 0.020 |
Why?
|
| Particle Size | 1 | 2010 | 122 | 0.020 |
Why?
|
| Adiposity | 1 | 2010 | 70 | 0.020 |
Why?
|
| Coronary Vessels | 1 | 2011 | 177 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 364 | 0.020 |
Why?
|
| Research Design | 1 | 2013 | 594 | 0.020 |
Why?
|
| ADAMTS13 Protein | 1 | 2009 | 3 | 0.020 |
Why?
|
| ADAM Proteins | 1 | 2009 | 11 | 0.020 |
Why?
|
| Epidemiologic Studies | 1 | 2009 | 17 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2010 | 165 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2010 | 318 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2010 | 223 | 0.020 |
Why?
|
| Thromboxane B2 | 1 | 2008 | 11 | 0.020 |
Why?
|
| Health Services Research | 1 | 2009 | 136 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 2009 | 114 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2010 | 280 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 858 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2009 | 267 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 204 | 0.020 |
Why?
|
| Recurrence | 1 | 2010 | 1139 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 1054 | 0.020 |
Why?
|
| Bronchopneumonia | 1 | 2006 | 1 | 0.020 |
Why?
|
| Disease Progression | 1 | 2011 | 1531 | 0.020 |
Why?
|
| Probability | 1 | 2007 | 355 | 0.020 |
Why?
|
| Efficiency, Organizational | 1 | 2006 | 58 | 0.020 |
Why?
|
| Benchmarking | 1 | 2006 | 78 | 0.020 |
Why?
|
| Feedback | 1 | 2006 | 133 | 0.020 |
Why?
|
| Opportunistic Infections | 1 | 2006 | 59 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2010 | 1823 | 0.020 |
Why?
|
| Prednisone | 1 | 2006 | 258 | 0.020 |
Why?
|
| Acute Disease | 1 | 2006 | 826 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 2006 | 220 | 0.020 |
Why?
|
| Mass Screening | 1 | 2009 | 617 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 916 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2006 | 230 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2007 | 1538 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 1034 | 0.010 |
Why?
|
| Incidence | 1 | 2007 | 1577 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 2601 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2006 | 977 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2007 | 2261 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2010 | 8477 | 0.010 |
Why?
|
| Animals | 1 | 2009 | 26582 | 0.010 |
Why?
|